Senior Scientist I, Cellular Neuroscience and Translational Pharmacology at Lexeo Therapeutics | NY, US | Rezi

Senior Scientist I, Cellular Neuroscience and Translational Pharmacology at Lexeo Therapeutics

Senior Scientist I, Cellular Neuroscience and Translational Pharmacology

Lexeo Therapeutics · NY, US

3 weeks ago

Senior Scientist I, Cellular Neuroscience and Translational Pharmacology

Lexeo Therapeutics · NY, US

a month ago
Resume preview

Impress employers and recruiters.
Choose from hundreds of resume examples.

Target Resume Now
Resume preview

Tailor your resume to this Senior Scientist I, Cellular Neuroscience and Translational Pharmacology role.

Rezi rewrites your resume against Lexeo Therapeutics's job description. Free.

Resume score gauge reading 58 out of 100

Don't guess if your resume is good enough.

See how it scores against the Senior Scientist I, Cellular Neuroscience and Translational Pharmacology posting at Lexeo Therapeutics — free, in seconds.

About the Role

We are seeking a highly collaborative, hands-on Senior Scientist I to establish a preclinical neuroscience laboratory supporting small-molecule and protein therapeutics. The role will focus on cellular profiling, lead selection, and building neuronal models and laboratory workflows.

Responsibilities

  • Lead a rapid, tiered cellular assay strategy for small-molecule lead optimization.
  • Lead cellular development of a transferrin-based protein replacement project by establishing quantitative assays.
  • Use orthogonal methods to distinguish surface-bound, internalized, degraded, and functionally delivered protein.
  • Establish fit-for-purpose neuronal culture models, including iPSC-derived neurons or glia.
  • Define assay controls, acceptance criteria, reproducibility standards, analysis plans, SOPs, sample tracking, and electronic documentation.
  • Translate data into concise recommendations to advance, modify, or discontinue assets.
  • Partner across protein engineering, chemistry, bioanalysis, DMPK, pathology, computational biology, and in vivo pharmacology.
  • Scientifically manage CROs and assay transfers.
  • Mentor junior scientists and build workflows that are reproducible across operators.
  • Future scope may include ASO screening in partnership with external experts.

Requirements

  • PhD in pharmacology, neuroscience, molecular biology, chemical biology, cell biology, or a related discipline.
  • 3 to 6 years of biotechnology or pharmaceutical industry experience.
  • Demonstrated experience in cellular pharmacology, assay development, and iterative drug discovery or lead optimization.
  • Hands-on experience with neuronal cell culture models, preferably human iPSC-derived neurons or glia.
  • Expertise in concentration-response, time-course, target-engagement, pharmacodynamic, quantitative data-analysis, and troubleshooting studies.
  • Concrete examples of scientific ownership in which an assay, platform, or data package influenced a program decision.
  • Excellent communication skills and willingness to maintain a substantial hands-on laboratory presence.

Skills

  • Enzyme biology
  • Epigenetics
  • Transcriptional pharmacology
  • Therapeutic proteins
  • Targeted-delivery constructs
  • Cellular uptake
  • Trafficking
  • Protein quantification
  • Mitochondrial functional assays
  • High-content imaging
  • Neuronal functional assays
  • Transferrin receptor biology
  • BBB transport
  • Biodistribution
  • Laboratory start-up
  • Assay transfer
  • CRO management
  • ASO screening
  • RNA pharmacology

Location

  • Northeast
  • Mid-Atlantic

Work Type

  • Hands-on laboratory presence

Experience Level

  • Senior Scientist I
  • 3 to 6 years of biotechnology or pharmaceutical industry experience

Education Level

  • PhD in pharmacology, neuroscience, molecular biology, chemical biology, cell biology, or a related discipline

Salary/Compensations

  • $143,500 - $160,000 a year

About the Company

  • Lexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease.
  • By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach.
  • The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.

Equal Opportunity

  • LEXEO Therapeutics is an EEO employer committed to an exciting, diverse, and enriching work environment.